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Abstract
The aspartic protease cathepsin-D (cath-D) is overexpressed by human epithelial breast cancer cells and is closely correlated
with poor prognosis in breast cancer. The adipocyte is one of the most prominent cell types in the tumor-microenvironment
of breast cancer, and clinical studies have shown that obesity increases the incidence of breast cancer. Here, we provide the
first evidence that cath-D expression is up-regulated in adipose tissue from obese human beings, as well as in adipocytes
from the obese C57BI6/J mouse. Cath-D expression is also increased during human and mouse adipocyte differentiation. We
show that cath-D silencing in 3T3-F442A murine preadipocytes leads to lipid-depleted cells after adipogenesis induction,
and inhibits of the expression of PPARc, HSL and aP2 adipocyte differentiation markers. Altogether, our findings
demonstrate the key role of cath-D in the control of adipogenesis, and suggest that cath-D may be a novel target in obesity.
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Introduction
The consumption of foods containing high levels of fat and
carbohydrates is a major cause of obesity, resulting in the
formation of excessive white adipose tissue. This increase in
adipose tissue mass results from a combination of hypertrophy of
existing adipocytes (hypertrophic adipocytes), and adipogenic
differentiation of precursor cells (adipocyte hyperplasia). Recently,
clinical studies have shown that obesity is a major risk factor for
cancer [1,2,3]. The presence of large amounts of adipose tissues
has been associated with poor prognosis for breast cancer in obese
postmenauposal women [4].
Interestingly, proteases have also been recently shown to affect
the biology of the adipocyte. The metalloproteinases [5,6] and the
cysteine cathepsins -K, -S and -L [7,8,9,10] stimulate adipogenesis,
and are up-regulated in obesity. In contrast, stromelysin 3 inhibits
adipogenesis and induces de-differentiation of adipocytes, gener-
ating a population of fibroblast-like cells that support the
desmoplastic reaction [11]. The aspartic protease cathepsin D
(cath-D), a marker of poor prognosis in breast cancer
[12,13,14,15,16], is overexpressed and secreted at high levels by
human epithelial breast cancer cells [17,18,19,20,21,22,23]. Cath-
D stimulates cancer cell proliferation, fibroblast outgrowth,
angiogenesis and metastasis [24,25,26,27,28,29,30,31,32,33,34].
Interestingly, we recently published that the novel cath-D
receptor, LRP1 (low-density lipoprotein receptor-related protein
1) [35], controls adipogenesis and is up-regulated in human and
mouse obese adipose tissue [36].
Here, we investigated the expression of cath-D in adipocytes
from obese subjects, and its role in the control of adipogenesis. We
show, for the first time, that cath-D expression is up-regulated in
mouse and human obese adipose tissues, as well as during mouse
and human adipogenesis. We also demonstrate that cath-D
silencing inhibits the adipogenic process, indicating the crucial
positive role of cath-D in adipogenesis.
Results
Cath-D expression is up-regulated in human and mouse
obese adipose tissue
Because of the recently established relationship between obesity
and cancer incidence [1,2,3], and of the demonstrated role of cath-
D in both cancer cells and stromal cells [21], we investigated cath-
D expression in human and mouse adipose tissues.
Cath-D mRNA expression was investigated in intra-abdominal
visceral adipose tissue (VAT) from lean and obese human subjects
(Figure 1A, panel a). Interestingly, cath-D mRNA was significantly
increased in the obese human visceral adipose tissue (Figure 1A,
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in subcutaneous adipose tissue (SAT) from lean and obese human
subjects (Figure 1A, panel b).
In order to find out whether this up-regulation of cath-D was a
general characteristic of adipocytes from obese subjects, we next
analysed cath-D mRNA levels in adipocytes isolated from
C57BI6/J mice fed either a High Fat Diet (HFD) or a Normal
Diet (ND) (Figure 1B). HFD-fed C57BI6/J mice exhibited
significantly higher body mass (47.661.4 g) than their control
littermates (31.161.2 g). Cath-D expression was significantly
greater in adipocytes from HFD obese mice than in those from
ND control mice (Figure 1B). Overall, our results indicate that
cath-D expression is up-regulated in adipose tissues of obese
human beings and mice.
Cath-D expression is increased in adipocytes during
adipogenesis in mouse and human
Since we were not aware of any report establishing that cath-D
protein is expressed in adipocyte cells, we analysed cath-D
expression in well-established mouse adipocyte cell lines (3T3-
F442A and 3T3-L1), and compared it to that in mouse fibroblasts
(NIH-3T3). Cath-D is synthesized as a 52-kDa precursor that is
rapidly converted in endosomes as an active 48-kDa single-chain
intermediate, and then in the lysosomes into the fully active
mature protease, composed of a 34 kDa heavy chain and a
14 kDa light chain. As Figure S1 shows, mouse cells mainly
expressed the intermediate 48 kDa cath-D form, and only to a
lesser extent the mature 34+14 kDa cath-D double chain, as
previously described [37]. Interestingly, cath-D expression was
increased in mature adipocytes in both the 3T3-F442A and 3T3-
L1 cell lines (Figure S1).
Obesity is characterized by the increased intracellular accumu-
lation of lipids, a characteristic of adipocyte differentiation that is
significantly correlated with adipocyte differentiation. Since cath-
D expression was up-regulated in obese tissues, we next
investigated whether cath-D plays any role in adipogenesis. We
first investigated the regulation of cath-D expression during the
course of differentiation of the 3T3-F442A preadipocyte cell line, a
valuable model of adipogenesis [38] (Figure 2). Interestingly, cath-
D mRNA (Figure 2A) and protein (Figure 2B) expression was
progressively up-regulated during adipogenesis. Since the overex-
pression of cath-D leads to the hypersecretion of the 52 kDa pro-
cath-D into the extracellular environment [19], we then
investigated whether adipocytes secrete 52 kDa pro-cath-D.
Secreted 52 kDa pro-cath-D was only detected in fully-differen-
tiated adipocytes from day 10 of differentiation (Figure 2B). To
validate our experimental conditions, we studied in parallel the
expression of PPARc (Figure 2A), HSL (Figure 2B) and aP2
(Figure 2A) adipocyte markers of differentiation. As expected, the
levels of these markers increased progressively during the
acquisition of the adipocyte phenotype (Figure 2A–B). In addition,
the amount of cytoskeletal b-actin protein decreased during
adipocyte differentiation, reflecting the change in cellular
morphology (Figure 2B), as previously described [39]. Interesting-
ly, a similar up-regulation of cath-D protein expression was
observed during 3T3-L1 adipocyte differentiation (Figure 3). It
was previously shown that cath-D expression was stimulated by
insulin in epithelial breast cancer cells [40,41]. To ensure that the
insulin treatment was not involved in the effect observed, we used
parental NIH-3T3 fibroblasts and fully-differentiated 3T3-F442A
adipocytes and. As shown in Figure 4, the levels of cath-D protein
remained unaffected in the adipogenic differentiation medium
both in NIH-3T3 fibroblasts (Figure 4A) and in mature 3T3-
F442A adipocytes (Figure 4B). We also confirmed that cath-D
protein expression was not altered in 3T3-F442A adipocytes by
insulin in dose-response experiments at low serum concentrations
(Figure 4C). Altogether, these results strongly suggest that cath-D
up-regulation is induced by the differentiation process per se and
not by insulin.
Figure 1. Cath-D expression is up-regulated in adipose tissues from obese human beings and mice. (A) Cath-D expression in
adipose tissue from lean and obese human subjects. The cath-D mRNA level was quantified in samples of human intra-abdominal visceral
adipose tissue (VAT) (panel a) and of human subcutaneous adipose tissue (SAT) (panel b) obtained from 27 morbidly (grade-III) obese patients (44.5+/
21.8 year old, BMI: 47.6+/21.3 kg/m
2) before they underwent bariatric surgery, and from 9 control patients about to undergo cosmetic abdominal
lipectomy (42.7+/24.5 year old, BMI: 23.1+/23.3 kg/m
2). Results are expressed as means +/2 SEM, *P,0.01 versus controls (normal VAT or normal
SAT). (B) Cath-D expression in adipocytes from obese mice. The cath-D mRNA level was quantified in adipocytes isolated from intra-abdominal
adipose tissues from 30-week-old, overweight C57Bl6/J mice fed a high-fat diet (HFD), and from C57Bl6/J control mice fed on normal diet (ND).
Results are means +/2 SEM from 5 mice for ND group and 4 mice for HFD group. *P,0.005 versus ND controls.
doi:10.1371/journal.pone.0016452.g001
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mental models, these preadipocytes have some distinct attributes
compared with human cells in primary culture beyond the obvious
species differences. We therefore next investigated the regulation
of cath-D expression during adipogenesis in human preadipocytes
purified from abdominal subcutaneous adipose tissue [42]
(Figure 5). These primary human cells were differentiated in an
efficient manner since about 75% of preadipocytes were converted
into the adipocyte phenotype (Figure 5A). As observed for the
mouse adipocyte, the expression of cath-D protein was also
Figure 2. Cath-D expression increases during 3T3-F442A adipogenesis. (A) Cath-D mRNA expression during adipogenesis. RNA
expression of cath-D, PPARc and aP2 were analysed in exponentially growing 3T3-F442A preadipocytes (Ex), in 3T3-F442A cells grown to confluence
(D0), and after culturing for the indicated days in adipogenic differentiation medium by real-time quantitative RT-PCR. Mean 6 SD values from 4
independent experiments is shown. P,0.05 versus confluent adipocytes. (B) Cath-D protein expression during adipogenesis. The expression
of the proteins cath-D, HSL, b-actin and ERK2 was analysed by immunoblotting in exponentially-growing 3T3-F442A preadipocytes (Ex), in 3T3-F442A
adipocytes grown to confluence (D0), and the times indicated after induction of the differentiation process. Pro-cath-D secreted for 24h was analyzed
during differentiation. ERK2 was used as a loading control. Similar results were observed in two independent experiments.
doi:10.1371/journal.pone.0016452.g002
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Taken together, these findings indicate that cath-D expression is
up-regulated during the differentiation of both mouse and human
preadipocytes.
Silencing of cath-D expression inhibits adipogenesis
Since cath-D was up-regulated in tissues from obese individuals,
and as its expression increased during the adipocytic process, we
went on to investigate whether preadipocytes require cath-D
expression to differentiate into mature adipocytes. Cath-D
expression was stably silenced in 3T3-F442A preadipocytes with
cath-D shRNA1 and shRNA2 generating the D10 and A4 clones,
respectively (Figure 6A). Control C34 and C37 clones were
obtained using Luc shRNA stably transfected into 3T3-F442A
preadipocytes (Figure 6A).
To evaluate the consequences of cath-D silencing on adipocyte
differentiation, we analysed the cellular lipid levels in adipocytes
which had or had not been silenced for cath-D at day 7 of
differentiation (Figure 6). Indeed, the most obvious feature of
adipocytes is the fact that they synthesise and store triglycerides in
lipid droplets and therefore the gradual development of lipid
droplets is characteristic of adipocyte precursor cells undergoing
adipogenic differentiation. Quantification of cath-D mRNA at day
7 of differentiation revealed a significant inhibition of cath-D
expression by 56+/22.4% and 60+/28.5% in A4 and D10
clones, respectively (Figure 6B, panel a). As illustrated in Figure 6B
(panel b), detection of neutral lipid by oil red O staining after 7
days of differentiation revealed that C34 and C37 clones
accumulated numerous large lipid droplets and adopted the
non-adherent, round morphology characteristic of mature 3T3-
F442A adipocytes. In contrast, in A4 and D10 clones silenced for
cath-D, the lipid droplets were markedly smaller and fewer in
number (Figure 6B, panel b). A4 and D10 clones retained the
morphology of adherent fibroblastic cells, suggesting that the
preadipocyte differentiation process did not occur in the absence
of cath-D (Figure 6B, panel b). Quantification of lipids
demonstrated that silencing cath-D in A4 and D10 clones resulted
in significantly lower lipid content at day 7 of differentiation than
in the C34 and C37 control clones (Figure 6B, panel c). We finally
analysed the expression of PPARc, HSL and aP2 adipocyte
differentiation markers in Luc and cath-D shRNA-transfected
3T3-F442A clones at day 7 of differentiation (Figure 6B, panel d).
Cath-D silencing was associated with inhibition of PPARc, HSL
and aP2 mRNA levels (Figure 6B, panel d). Taken together, these
findings indicate that cath-D silencing in preadipocytes inhibits
adipogenesis, leading to lipid-depleted cells.
Discussion
Our results demonstrate, for the first time, that cath-D expression
is up-regulated in abdominal visceral and subcutaneous tissues from
obese human subjects. A previous study observed cath-D mRNA
expression in abdominal subcutaneous adipose tissue [43]. This up-
regulation of cath-D expression in the VAT and SAT of
overweight/obese patients is consistent with our data from obese
mice. Obesity is characterized by increased intracellular accumu-
lation of lipids, which is significantly correlated with adipocyte
differentiation. Terminally differentiated adipocytes cannot divide,
which means that any increase in the number of adipocytes in the
bodymustresultfromthedifferentiationofpreadipocytes,whichact
as a renewable source of adipocytes.
Our data show that cath-D expression increases gradually as
3T3-F442A and 3T3-L1 cells differentiate into mature adipocytes.
Interestingly, our findings also reveal that fully-differentiated 3T3-
F442A adipocytes secrete pro-cath-D, suggesting a potential new
function as an adipokine. A recent study analysing the secretome of
adipocytes reported that cath-D is a secretory protein induced by
insulin [44]. Most functional studies of adipocyte differentiation and
function have been performed using the murine adipogenic 3T3-L1
and 3T3-F442A cell lines or genetically-modified mice. However,
there are fundamental differences in lipoprotein metabolism
between mice and human beings [45]. This is why it was important
to investigate the regulation of cath-D expression in human
adipocytes. We observed the up-regulation of cath-D during
adipogenesis in a primary culture of preadipocytes isolated from
human sub-cutaneous adipose tissue. Interestingly, cath-D expres-
sion has also been shown to be markedly increased during the
differentiation process in primary cultures of brown adipocytes [46].
Our report highlights that cath-D silencing by shRNAs in 3T3-
F442A preadipocytes leads to lipid-depleted cells, and to a
reduction of the expression of PPARc, HSL and aP2 adipocyte
markers of differentiation, indicating the essential role of cath-D in
the differentiation process of preadipocytes. Given that cath-D
protein is required for adipocyte differentiation and as it is
abundantly expressed in fully-differentiated adipocytes, we pro-
pose that cath-D may be involved in the onset of obesity.
Moreover, murine cath-D deficiency led to the accumulation of
cholesteryl esters in the brain, suggesting that cath-D may play a
key role in lipid metabolism [47].
Taken together, our findings reveal that cath-D is up-regulated
in tissues from obese humans and mice, and that it is a novel key
regulator of adipogenesis. We propose that targeting cath-D in
obesity could reduce the number of hypertrophic adipocytes and
decrease adipocyte hyperplasia. In the future, we intend to
investigate the mechanism(s) by which cath-D controls adipogen-
esis. Since experimental studies have demonstrated that adipocytes
play a supportive role in breast growth [48,49,50], and as clinical
studies have shown that obesity increases the incidence of breast
cancer [1,2,3], we will analyse the role of cath-D up-regulation in
obese adipocytes with regard to cancer.
Figure 3. Cath-D expression increases during 3T3-L1 adipo-
genesis. Protein expression of cath-D was analysed by immunoblot-
ting in 3T3-L1 adipocytes grown to confluence (D0), and after the
differentiation process had been induced for the indicated days. The
pro-cath-D secreted over 48h was monitored during differentiation.
ERK2 was used as loading control.
doi:10.1371/journal.pone.0016452.g003
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Ethics Statement
All subjects gave their informed written consent to participate to
the study.
Our protocol is using adipose tissues from plastic surgery
considered as ‘‘waste’’, and we thus do not need a specific agreement.
However the study was performed accordingly to the declaration of
Helsinki as revised in 2000 (http://www.wma.net/e/policy/b3.htm)
and approved by the Ethical commitee of the Rangueil hospital
(Toulouse, France) with permit number 07/858/03/07. Mice were
handled in accordance with National Institute of Medical Research
(INSERM) principles and guidelines. C57Bl6/J female mice were
obtained from Charles River laboratory (l’Arbresle, France). Philippe
Valet, with the license number # 31–147 given by the French
government, performed the experiments on the animals. This study
was approved by the ethics committee of Midi-Pyre ´ne ´es (France) with
the permit number MP/01/01/01/2010.
Figure 4. Effect of insulin on cath-D expression in NIH-3T3 fibroblasts and 3T3-F442A adipocytes. (A) Cath-D expression in parental
NIH-3T3 fibroblasts in the presence or the absence of the adipogenic differentiation medium. Parental NIH-3T3 fibroblasts were grown
or not for 8h, 24h and 48h in adipogenic differentiation medium (diff. medium). Cath-D protein expression was analysed by immunoblotting, and
ERK2 was used as loading control. (B) Cath-D expression in mature adipocytes in the presence or the absence of the adipogenic
differentiation medium. 3T3-F442A adipocytes differentiated for 10 days were grown or not for 8h, 24h and 48h in adipogenic differentiation
medium (diff. medium). Cath-D protein expression was analysed by immunoblotting, and ERK2 was used as loading control. (C) Effect of
increasing doses of insulin on cath-D expression in adipocytes. 3T3-F442A adipocytes differentiated for 10 days were treated with increasing
doses of insulin (6.25 nM to 50 nM) in 0.5% or 1% FCS for 24h. Cath-D protein expression was analysed by immunoblotting. ERK2 served as loading
control.
doi:10.1371/journal.pone.0016452.g004
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Cell lines were cultured in DMEM (Invitrogen) supplemented
with 10% fetal calf serum (FCS). Differentiation was induced by
incubating confluent 3T3-F442A cells in differentiation medium
(DMEM supplemented with 10% FCS and 50 nM insulin) as
described [45]. Differentiation was induced by incubating 3T3-L1
confluent cells in differentiation medium (DMEM supplemented
with 10% FCS and 10 mg/ml insulin, 250 mM isobutylmethyl-
xanthine, 1 mM rosiglitazone, 1 mM dexamethasone).
RNA extraction and analysis
Total RNA was extracted using the Reasy minikit (QIAGEN
Sciences, Maryland) according to the manufacturer’s instructions.
Reverse transcription of total RNA was performed at 37uC using
Moloney murine leukemia virus reverse transcriptase enzyme
(Invitrogen, Carlsbad, CA) and random hexanucleotide primers
(Promega, Madison, WI). Quantitative PCR was carried out by
real-time PCR using a LightCycler and the DNA double-strand-
specific SYBR green I dye for detection (Roche, Basel,
Switzerland). Results for mouse RNA were normalized to RS9
levels. For human RNA, analysis of the 18 S ribosomal RNA was
performed in parallel using the ribosomal RNA control Taqman
Assay Kit (Applied Biosystem) to normalize gene expression.
The sequences of the primers were:
mouse RS9 (sens 59CGGCCCGGGAGCTGTTGACG39,
reverse 59CTGCTTGCGGACCCTAATGTGACG39),
mouse aP2 (sens 59AACACCGAGATTTCCTTCAA39, re-
verse 59AGTCACGCCTTTCATAACACA39),
mouse cath-D (sens 59TTCGTCCTCCTTCGCGATT39; re-
verse
59TCCGTCATAGTCCGACGGATA39)
mouse HSL (sens 59CTGAAGGCTCTGAGTTGGTCAA39,
reverse 59GGCTTACTGGGCACAGATACCT39),
mouse PPARc (sens 59 AGGCCGAGAAGGAGAAGCTG-
TTG39, reverse 59TGGCCACCTCTTTGCTCTGCTC39),
human cath-D (59TTGCTGTTTTGTTCTGTGGTTTTC9,
reverse 59CAGACAGGCAGGCAGCATT39).
Stable transfection of shRNAs in 3T3-F442A cells
3T3-F442A cells were transfected with 1 mg of shLuc, anti-cath-
D shRNA1 or shRNA2 expression vectors (Invivogen) using
Nucleofector Technology (Amaxa biosystems) according to the
manufacturer’s instructions and 40 clones resistant to Blasticidin
(4 mg/ml) were isolated. Clone D10 transfected with anti-cath-D
shRNA1 and clone A4 transfected with anti-cath-D shRNA2 were
the best clones selected for cath-D silencing.
sh1 59GGTTCCATGTAAGTCTGACCATCAAGAGTGG-
TCAGACTTACATGGACCC39
sh2 59GACCAGTCAAAGGCAAGAGGTTCAAGAGACCT-
CTTGCCTTTGACTGGTC39
Oil Red O staining
Adipocytes were washed with phosphate-buffered saline
(pH 7.4) and then fixed with Antigenfix (Diapath, Italy). Cells
were stained with Oil Red O dye (saturated Oil Red O dye in six
parts of isopropanol and four parts of water), an indicator of cell
lipid content, and then exhaustively rinsed with water. Spectro-
photometric quantification of the stain was performed by
dissolving the stained oil droplets in the cell in isopropanol and
measuring their absorbance at 540 nm.
Human samples
Human adipose tissue was collected according to the guidelines
of the Ethical Committee of Toulouse-Rangueil and Nancy J.
d’Arc Hospitals and with the full ethical approval of the Ethical
Committee of Toulouse-Rangueil and Nancy J. d’Arc Hospitals.
Figure 5. Expression of cath-D during adipogenesis in human. (A) Micrographs of human adipocytes. Human preadipocytes isolated
from subcutaneous adipose tissue digested with collagenase and separated from the stromal vascular fraction were grown for 0, 3, 7 and 14 days in
the presence of the adipogenic medium as illustrated in the micrographs. A representative experiment is shown. (B) Cath-D expression during
adipogenesis. Protein expression of cath-D and HSL was analysed by immunoblotting after the indicated time following induction of the
differentiation process (panel a). Ku70 was used as loading control, as previously described [52]. One representative experiment out of 2 is shown.
doi:10.1371/journal.pone.0016452.g005
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the study. Human abdominal visceral (VAT) adipose tissue and
human subcutaneous adipose tissue (SAT) samples were obtained
from 9 healthy volunteer patients (42.7+/24.5 yr old, BMI:
23.1+/23.3 kg/m
2) undergoing cosmetic abdominal lipectomy.
No clinical data from these patients were available. Human VAT
adipose tissue samples were obtained from 27 morbidly (grade-III)
obese subjects (44.5+/21.8 yr old, BMI: 47.6+/21.3 kg/m
2)
before they underwent bariatric surgery.
All subjects were drug-free, and were not suffering from any
disorder other than obesity. Tissue samples were immediately
frozen in liquid nitrogen, and stored at 280uC. Total RNAs were
extracted from isolated adipocytes, and their cath-D expression
analysed by RT-PCR.
For in vitro differentiation, human preadipocytes were isolated
from human subcutaneous adipose tissue obtained from patients
undergoing abdominal lipectomy in the plastic surgery department
of Rangueil Hospital (Toulouse, France) with the approval of the
locals Ethic Committee. All subjects gave their informed written
consent to participate in the study. Adipose tissue fragments were
immediately used for collagenase digestion, as previously described
[42]. The digestate was centrifuged to separate the adipocytes
from the stroma-vascular fraction, which contained preadipocytes
(pellet). Cells isolated from the SVF fraction were induced to
differentiate into adipocytes as previously described [51]. Briefly,
confluent cells (day 0) were induced to differentiate in DMEM/
Ham’s F12 (1:1) medium containing 0.01 mg/ml transferrin,
100 nM cortisol, 0.2 nM triiodothyronine, and 20 nM insulin. To
trigger differentiation, 25 nM dexamethasone, 500 mM IBMX
and 2 mM rosiglitazone were included from day 0 to day 4.
Intracellular accumulation of lipid droplets became clearly evident
at day 10 [42].
Mice
Mice were handled in accordance with National Institute of
Medical Research (INSERM) principles and guidelines. C57Bl6/J
female mice were obtained from Charles River laboratory
(l’Arbresle, France). Mice were housed conventionally in an
animal room at constant temperature (20–22uC) and humidity
(50–60%), and with a 12 h light–dark cycle. All the mice had free
access to food and water throughout the experiment. The
C57Bl6/J mice were assigned to a normal diet (ND) or high-fat
diet (HFD) (SAFE, France). The energy contents of the diets were
as follows: 20% protein, 70% carbohydrate, and 10% fat for the
ND; and 20% protein, 35% carbohydrate, and 45% fat for the
HFD. The main source of fat in the HFD was lard (20 g/100g of
food). C57Bl6/J mice (initially 10 weeks old) were fed an ND or
HFD for 20 weeks. A 20 weeks period of HFD is used to mimic the
slow development of obesity in humans associated with the
settlement of insulin resistance and low grade inflammation. All
the mice were sacrificed at 30 weeks of age.
Isolation of adipocytes from mouse adipose tissue
Mouse intra-abdominal adipose tissues were dissected immedi-
ately after sacrifice, minced in 5 ml of Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies, Inc., Invitrogen, Paisley, UK)
supplemented with 1 mg/ml collagenase (SIGMA) and 1% BSA for
30 min at 37uC while shaking. Digestion was followed by filtration
througha150 mmscreen,andthefloatingadipocyteswereseparated
from the medium containing the stroma-vascular fraction (SVF).
Adipocytes were washed twice in DMEM, and then processed for
RNA extraction using the RNeasy mini kit (Qiagen, Germany).
Immunoblots
Cells were lysed in lysis buffer (50 mM HEPES pH 7.5,
150 mM NaCl, 10% glycerol, 1% Triton X100, 1.5 mM MgCl2,
1 mM EGTA, 100 mM NaF, 10 mM NaPPI, 500 mm Na-
Vanadate, 1 mM PMSF, 10 mM Aprotinine, and a protease
inhibitor cocktail). After shaking gently for 20 min at 4uC, cell
extracts were obtained by centrifugation in a microfuge at
13,000 rpm for 15 min at 4uC. Equal amounts of protein
(100 mg) from cell extracts, quantitated by the Bradford assay,
were separated on a 7% gel by SDS-PAGE. Proteins were electro-
transferred to a PVDF membrane, and then incubated with 1 mg/
ml anti-mouse cath-D (Santa Cruz Biotechnology), 1 mg/ml anti-
human cath-D (BD Biosciences), 1 mg/ml anti-a tubulin (Lab
Vision Corporation), 1 mg/ml anti-b actin (Sigma), 1 mg/ml
ERK2 (Santa Cruz Biotechnology), or 0.4 mg/ml anti-HSL (Santa
Cruz Biotechnology). Proteins were visualized with horseradish
peroxidase-conjugated sheep anti-mouse immunoglobulin (ECL
Amersham) or horseradish peroxidase-conjugated rabbit anti-goat
immunoglobulin (ECL Amersham) followed by the Renaissance
chemiluminescence system (Perkin Life Sciences).
Statistical analysis
Results are expressed as means 6 SEM. Statistical differences
between two groups were evaluated using Student’s t tests. The
level of significance was set at P,0.05.
Supporting Information
Figure S1 Cath-D expression in preadipocytes, adipo-
cytes, and fibroblasts. Cath-D expression was analysed by
immunoblotting confluent preadipocytes (D0), and adipocytes
differentiated for 7 days (D7) from the 3T3-F442A and 3T3-L1
preadipocytic cell lines, and NIH-3T3 mouse fibroblasts. a-tubulin
was used as a loading control.
(TIF)
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Figure 6. Silencing of cath-D in 3T3-F442A preadipocytes inhibits adipogenesis. (A) Silencing of cath-D by shRNAs in 3T3-F442A
preadipocytes. 3T3-F442A preadipocytes were stably transfected with Luc shRNA (C34 and C37 clones), cath-D shRNA1 (D10 clone) and cath-D
shRNA2 (A4 clone). Cath-D expression was monitored by immunoblotting in C34, C37, A4, and D10 clones. a-tubulin was used as a loading control.
(B) Extinction of cath-D expression in 3T3-F442A preadipocytes inhibits adipogenesis. Luc shRNA (C34 and C37) and cath-D shRNA (A4
and D10) clones were maintained for 7 days in the adipogenic differentiation medium. Cath-D mRNA expression was quantified in C34, C37, A4 and
D10 clones at day 7 of differentiation (panel a). Mean 6 SD of 3 independent experiments is shown. *P,0.005 versus the C37 clone. Micrographs of
Luc shRNA (C34 and C37) and cath-D shRNA (A4 and D10) clones were performed at day 7 of differentiation (panel b). One representative experiment
out of 3 is shown. The lipid content was quantified at day 7 of differentiation in Luc shRNA (C34 and C37) and cath-D shRNA (A4 and D10) clones
(panel c). Mean 6 SD of triplicate of is shown. *P,0.025 versus the C37 clone. Expression of PPARc, HSL and aP2 mRNA was analysed in Luc shRNA
clones (C34 and C37) or cath-D shRNA clones (A4 and D10) after 7 days in the adipogenic differentiation medium (panel d). One representative
experiment out of 2 is shown.
doi:10.1371/journal.pone.0016452.g006
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